Clinical trialNCT05852431CompletedPhase 3Interventional

To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia

Sponsor89bio, Inc.Enrollment369Severe Hypertriglyceridemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

To determine the effect of Pegozafermin on fasting serum triglyceride levels in subjects with Severe Hypertriglyceridemia (TG ≥500 to ≤2000 mg/dL) after 26 weeks of treatment.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Teresa Parli, MD
89bio, Inc.
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

177 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Argentina

89bio Clinical Study Site
Rosario, Santa Fe Province, Argentina
89bio Clinical Study Site
Buenos Aires, Argentina
89bio Clinical Study Site
Buenos Aires, Argentina
89bio Clinical Study Site
Buenos Aires, Argentina
89bio Clinical Study Site
Córdoba, Argentina
89bio Clinical Study Site
Córdoba, Argentina
89bio Clinical Study Site
Córdoba, Argentina
89bio Clinical Study Site
Córdoba, Argentina
89bio Clinical Study Site
Córdoba, Argentina
89bio Clinical Study Site
Mendoza, Argentina
89bio Clinical Study Site
Rosario, Argentina
89bio Clinical Study Site
San Miguel de Tucumán, Argentina
89bio Clinical Study Site
Viedma, Argentina

Austria

89bio Clinical Study Site
Graz, Austria
89bio Clinical Trial Site
Vienna, Austria
89bio Clinical Trial Site
Vienna, Austria

Belgium

89bio Clinical Study Site
Edegem, Belgium
89bio Clinical Study Site
Ghent, Belgium
89bio Clinical Study Site
Haine-Saint-Paul, Belgium
89bio Clinical Study Site
Yvoir, Belgium

Bulgaria

89bio Clinical Trial Site
Botevgrad, Bulgaria
89bio Clinical Study Site
Dimitrovgrad, Bulgaria
89bio Clinical Trial Site
Plovdiv, Bulgaria
89bio Clinical Study Site
Sliven, Bulgaria
89bio Clinical Trial Site
Sliven, Bulgaria
89bio Clinical Study Site
Sofia, Bulgaria
89bio Clinical Study Site
Sofia, Bulgaria
89bio Clinical Study Site
Sofia, Bulgaria
89bio Clinical Study Site
Sofia, Bulgaria
89bio Clinical Trial Site
Sofia, Bulgaria
89bio Clinical Study Site
Veliko Tarnovo, Bulgaria
89bio Clinical Trial Site
Veliko Tarnovo, Bulgaria

Canada

89bio Clinical Study Site
North Vancouver, British Columbia, Canada
89bio Clinical Study Site
Brampton, Ontario, Canada
89bio Clinical Study Site
Chicoutimi, Quebec, Canada
89bio Clinical Study Site
Laval, Quebec, Canada
89bio Clinical Study Site
Montreal, Quebec, Canada
89bio Clinical Study Site
Québec, Quebec, Canada

Chile

89bio Clinical Study Site
Concepción, Chile
89bio Clinical Study Site
Santiago, Chile

137 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PegozaferminPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 15 Jun 2023
Primary completion: 7 Jul 2025
Completion: 9 Apr 2026
Last update posted: 7 Jul 2026
Registered enrollment: 369
Registry id: NCT05852431

Cross-registrations

EU-CTR / CTIS (EudraCT)2023-503576-25-00

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 4 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.